Background: Familial progressive hyper-and hypopigmentation (FPHH) is a rare genodermatosis that is characterized by diffuse hyper-and hypopigmented spots on the skin and mucous membranes. It is caused by a pathogenic mutation of the KITLG gene. oBjectives: To investigate the clinical features and mutation of the KITLG gene in a Chinese family with FPHH. Methods: Histopathological and immunohistochemical analysis of lesions from the proband was performed. The KITLG gene was screened for the presence of mutations. results: A Chinese family containing 14 individuals with FPHH was described, and the proband was a 5-year-old girl showing diffuse hyper-and hypopigmented lesions on her extremities and trunk. Histopathological and immunohistochemical staining for S100 and HMB45 of skin biopsy specimens from the hyperpigmented areas showed a striking increase in melanin throughout the epidermis, especially in the basal cell layer, and staining of hypopigmented area specimens displayed lower levels of melanin in the epidermis. Mutation analysis of the KITLG gene was performed, but no mutation was found. study liMitations: The new pathogenic gene was not found. conclusion: A family with FPHH was described. Analysis revealed that its members did not have any mutations of the KITLG gene, which provided evidence for genetic heterogeneity of this genodermatosis.
INTRODUCTION
Familial progressive hyperpigmentation (FPH) is an autosomal dominant disorder that was first reported in four affected individuals in two generations of an African-American Family. 1 Its clinical signs consist of progressive, diffuse, partly blotchy hyperpigmented lesions presenting at birth, which increase in size and number with age. 2 Cafe-au-lait macules and larger hypopigmented ash-leaf macules also appear in FPH. Familial progressive hyper-and hypopigmentation (FPHH) is distinct from FPH without hypopigmentation. Patients with FPHH often don't have systemic symptoms, but there is a familial pattern. 3 A genome-wide linkage analysis of seven families with FPHH was performed, and it identified a linkage on 12q21.12-q22 in a recent report. 4 Then, the mutations of a single gene, KITLG, were discovered to cause various pigmentation disorders: FPH, FPHH, and likely dyschromatosis universalis hereditaria 2 (DUH2). The gain-of-function mutation of the KITLG gene affects melanin synthesis and causes familial progressive hyperpigmentation, and importantly, KITLG is expressed locally in the epidermal keratinocytes and endothelial cells of human skin. 5, 6 The KITLG gene and its receptor, KIT, play important roles in modulating melanocyte proliferation and pigment production. 7 Here, we describe a Chinese family with FPHH using clinical, histopathological, immunohistochemical (IHC) and mutation analyses.
METHODS

Subjects
A four-generation Chinese family had 14 individuals affected by FPHH (9 men and 5 women) and had pedigrees that showed an autosomal dominant inheritance pattern ( Figure 1 ). The proband (III:7) was a 5-year-old girl. Extensive hyper-and hypopigmentation with irregular patches was found at one week of age, and over time, the patches progressed successively over the thigh, waist, back, chest, upper limb, and dorsum of the hands and feet, sparing only the face, palms, soles and oral mucosa. The hyperpigmentation was more intense at the age of 5 years than it was at 2 years, but there was no obvious change in the hypopigmentation (Figure 2 ). There were deep bronze-brown patches and irregular hypopigmented spots intermixed on her limbs and trunk without any systemic disease. The child was born to healthy, non-consanguineous parents following an uneventful pregnancy and eutocia. 
Histopathological and IHC staining
Skin biopsy specimens from the proband were stained with hematoxylin and eosin (HE). IHC staining for S100 and HMB45 was performed on formalin-fixed and paraffin-embedded sections of the lesions using the Elivision two-step system (Maixin Biotech Inc., Fuzhou, China). First, the tissue sections were deparaffinized, and they were rehydrated and subjected to microwave antigen retrieval in citrate buffer (pH 6.0). Inhibition of endogenous peroxidase activity was accomplished by incubating the slices in 3% H 2 O 2 peroxidase inhibitor. After washing three times in phosphate buffered saline (PBS), the sections were incubated with a primary antibody against S100 or HMB45 (in operating fluid) at 4°C overnight. Then, the sections were incubated with a biotinylated secondary antibody at room temperature for 10min. Staining procedures were performed according to the manufacturer's instructions.
Mutation analysis
Genomic DNA was extracted from ten affected and three unaffected individuals using the Qiagen Blood DNA Kit (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer's instructions. Screening for mutations in the KITLG gene was performed.
We amplified the entire coding region of KITLG to span the open reading frame encoding for exons 1-9. After the reference sequence of the KITLG gene was obtained from the Genebank database, we produced the primer sequences using the Primer 3.0 program (Table   1) . PCR was performed using 15μl of a reaction mixture that con- and an extension at 72°C for 55s, with a final extension at 72°C for 10 min. After amplification, the products were purified using a QIAquick PCR Purification Kit (QIAGEN Inc., Valencia, CA, USA) and were directly sequenced on an Applied Biosystems 3730XL Sequencer (Carlsbad, CA, USA). Sequence comparisons and analysis were performed using the Chromas Version 12.0 software.
RESULTS
Histopathological and IHC staining
HE staining revealed a clear increase in melanin throughout the epidermis of the hyperpigmented tissue, particularly in the basal cell layer, and it revealed lower levels of melanin in the hypopigmented tissue. The S100 staining of hyperpigmented areas showed clear, dark staining in the nucleus and cytoplasm of both the epidermis and some dermis cells, especially in the basal layer.
These darkly stained regions indicated a large number of melanocytes and melanin and possibly Langerhans cells due to a lack of S100 specificity. HMB45 staining of the hyperpigmented tissue was similar to that of S100 in the same area with increased melanocytes and melanin, but there was little staining in the nucleus and dermis compared with S100. The staining for S100 and HMB45 were almost completely negative in the hypopigmentation areas. These findings were consistent with the HE staining ( Figure 3 ). The diagnosis of FPHH was made based on the clinical features and family history.
Mutation analysis
The results from sequencing of ten affected and three un- Increase in pigmentation was rapid during childhood and slowed
FIgure 3: Histopathological and immunohistochemical features( Hematoxylin & eosin x400). HE staining (A1),
Immunohistochemical staining for S100 (A2) and HMB45 (A3) respectively from hyperpigmentation; HE staining (B1), Immunohistochemical staining for S100 (B2) and HMB45 (B3) respectively from hypopigmentation ison with her symptoms at 2 years old, at 5 years old, we found that the hyperpigmented patches had further progressed in size and number, though only to a small degree. Menstruation did not appear to affect the disorder in women of this family. Due to the differences in race and complexion, the patients' phenotypes were not entirely the same as in the cases reported previously.
In this study, the histopathology of lesions presented that a marked increase in the amount of melanin in the basal cell layer of hyperpigmented area, and lower level of melanin in hypopigmented areas. The dermis was normal and no melanophages were seen. Keratinocytes had a larger number of melanin granules than normal and some of the granules displayed free melanosomes, but others within the phagosomes were displayed in a caucasoid pattern under electron microscopy. 16 For ultrastructure, hypomelanotic skin showed small melanosomes within melanosome complexes in keratinocytes, on the contrary, hypermelanotic skin showed large melanosomes distributed singly in keratinocytes. 12 In general, the histopathological features of this disease were similar in reports of different cases or families. 1, 3, 5, [8] [9] [10] IHC staining for S100 and HMB45 was also performed. S100
is a commonly used marker to stain Langerhans cells, melanocytes, and Pacinian corpuscles in dermatology. HMB45 recognizes melanocytes with a high degree of specificity. IHC staining for S100 and HMB45 showed clearly higher levels of melanin in hyperpigmented areas and the opposite result in hypopigmented areas, which was similar to the histopathology results in our study. Cardinali et al. per- formed IHC staining in tissue from two FPH patients and found an increased expression of hepatocyte growth factor (HGF), stem cell factor (SCF) and keratinocyte growth factor (KGF) in fibroblast-like cells of the upper dermis in hyperpigmented lesions. 17 We did not found S100 and HMB45 staining in the previous studies of FPHH.
Based on the clinical and pathological presentation, the patients were diagnosed with FPHH. The patients in this family displayed massive hyper-and hypopigmentation lesions that spared only the face, palms, soles and oral mucosa and that showed different features from those presented in the majority of cases previously reported, but similar to those in a case reported by Zanardo. a genome-wide scan for linkages in a previously described Chinese family with FPH. 8 The locus was mapped to chromosome 12q21.31-q23.1 via two-point linkage analysis, and a gain-of-function missense mutation in the KITLG gene was found to be cosegregated in affected individuals in this family. In another report, linkage analysis was performed in seven families. Five of these families were related and were from southeastern Germany, whereas the other two were from America and Denmark. 4 Three Germanic and one American family among these were described previously. 3, 11 Multipoint analysis mapped the locus to chromosome 12q, and an analysis of two additional German families with FPHH showed the same result. 3 Two heterozygous missense mutations were found in two unrelated Caucasian families with FPHH. 15 This study confirmed that the gene underlying FPHH is the KITLG gene, which has also been demonstrated in separate studies. 4, 5 We performed a mutation analysis of the KITLG gene; however, this sequencing analysis did not show any mutation of the KITLG gene in the ten affected individuals. The experimental process was repeated several times, and the same results were found.
Amyere et al. screened KITLG in seven families and did not find any mutation in the coding regions of KITLG in three of the families. 4 Based on the typical clinical features and the fact that there were no mutations found in the coding regions of the KITLG gene in the family with FPHH presented here, we believe that FPHH is a heterogeneous genetic disease and that it is caused by more than one genetic locus.
